Insulet (PODD) announced an update on their ongoing clinical study. Study Overview Insulet’s new study, officially titled “Safety and Efficacy of the Omnipod® SmartAdjust 2.0 System Compared to the ...
Insulet (PODD) announced an update on their ongoing clinical study. Study Overview: Insulet Corporation is running a new clinical study titled “An Evaluation of the Omnipod® M System in Adults With ...
Pease announced, "For the fourth quarter, we expect total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28%." She guided for fourth quarter U.S. Omnipod growth of 24% to 27% ...
Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) system commercially available in Canada for people with type 1 diabetes (ages two years and above). Omnipod 5 is ...
New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents. PODD shares are rallying today. Track live prices here. The automated ...
CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong demand and adoption of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback